Journal article

Combination Gefitinib and Methotrexate Compared With Methotrexate Alone to Treat Ectopic Pregnancy

Monika M Skubisz, Andrew W Horne, Terrance G Johns, Ulrika W Nilsson, W Colin Duncan, Euan M Wallace, Hilary OD Critchley, Stephen Tong

OBSTETRICS AND GYNECOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013

Abstract

OBJECTIVE: To determine the safety, tolerability, and efficacy of combination gefitinib and methotrexate to treat ectopic pregnancy. METHODS: We performed a phase I, single-arm (nonrandomized), open-label study. Twelve women with ectopic pregnancies were administered methotrexate (50 mg/m, intramuscular) and 250 mg oral gefitinib in a dose-escalation protocol: one dose (day 1) n=3; three doses (days 1-3) n=3; seven doses (days 1-7) n=6. Efficacy was examined by comparing human chorionic gonadotrophin (hCG) decline and time to resolution with historic controls administered methotrexate only. RESULTS: Common side effects were transient acneiform rash in 67% (8/12) and diarrhea in 42% (5/12) of..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC) Project


Awarded by NHMRC Career Development Fellowship


Awarded by Medical Research Council Centenary Award


Awarded by Medical Research Council


Awarded by Chief Scientist Office


Funding Acknowledgements

Supported by National Health and Medical Research Council of Australia (NHMRC) Project Grants #606611 (S. T. and T.G.J.) and #1008276 (S. T., E. M. W., and T.G.J.); NHMRC Career Development Fellowship #1050765 (S. T.); The Monash Institute of Medical Research Flagship Grant (S. T., T.G.J., E. M. W.); Medical Research Council Clinician Science Fellowship (A. W. H.); Medical Research Council Centenary Award #G0802808 (A. W. H.); The Helen MacPherson Trust (S. T.); and The Victorian Government's Operational Infrastructure Support Program (M. S., T.G.J., and E.M.W.).